Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.

PURPOSE We use changes in tumor measurements to assess response and progression, both in routine care and as the primary objective of clinical trials. However, the variability of computed tomography (CT) -based tumor measurement has not been comprehensively evaluated. In this study, we assess the variability of lung tumor measurement using repeat CT scans performed within 15 minutes of each other and discuss the implications of this variability in a clinical context. PATIENTS AND METHODS Patients with non-small-cell lung cancer and a target lung lesion ≥ 1 cm consented to undergo two CT scans within a period of minutes. Three experienced radiologists measured the diameter of the target lesion on the two scans in a side-by-side fashion, and differences were compared. RESULTS Fifty-seven percent of changes exceeded 1 mm in magnitude, and 33% of changes exceeded 2 mm. Median increase and decrease in tumor measurements were +4.3% and -4.2%, respectively, and ranged from 23% shrinkage to 31% growth. Measurement changes were within ± 10% for 84% of measurements, whereas 3% met criteria for progression according to Response Evaluation Criteria in Solid Tumors (RECIST; ≥ 20% increase). Smaller lesions had greater variability of percent measurement change (P = .005). CONCLUSION Apparent changes in tumor diameter exceeding 1 to 2 mm are common on immediate reimaging. Increases and decreases less than 10% can be a result of the inherent variability of reimaging. Caution should be exercised in interpreting the significance of small changes in lesion size in the care of individual patients and in the interpretation of clinical trial results.

[1]  P. LoRusso,et al.  Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction? , 2010, Clinical Cancer Research.

[2]  M. Buyse,et al.  Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Binsheng Zhao,et al.  Pulmonary metastases: effect of CT section thickness on measurement--initial experience. , 2005, Radiology.

[4]  K. Hopper,et al.  Analysis of interobserver and intraobserver variability in CT tumor measurements. , 1996, AJR. American journal of roentgenology.

[5]  L. Washington,et al.  Inherent variability of CT lung nodule measurements in vivo using semiautomated volumetric measurements. , 2006, AJR. American journal of roentgenology.

[6]  William Pao,et al.  Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Wendy J. Post,et al.  Volumetric measurement of pulmonary nodules at low-dose chest CT: effect of reconstruction setting on measurement variability , 2009, European Radiology.

[8]  Binsheng Zhao,et al.  Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. , 2009, Radiology.

[9]  L. Schwartz,et al.  Evaluation of tumor measurements in oncology: use of film-based and electronic techniques. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Heber MacMahon,et al.  Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. , 2004, Medical physics.

[11]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[12]  L. Broemeling,et al.  Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Richard Pazdur,et al.  Accelerated approval and oncology drug development timelines. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[15]  Michael L Maitland,et al.  Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. , 2007, Journal of the National Cancer Institute.

[16]  J. Blay,et al.  Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Escudier,et al.  Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Manish R. Sharma,et al.  A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies. , 2010 .

[19]  W. Heindel,et al.  Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility , 2003, European Radiology.

[20]  William Pao,et al.  A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development , 2010, Clinical Cancer Research.

[21]  Michael L Maitland,et al.  Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis , 2010, Clinical Cancer Research.

[22]  Ivan Pedrosa,et al.  Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. , 2011, European Urology.